This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard Slataper, MD; Nancy Vicknair, AB; Rebecca Sadler, LRD; George L. Bakris, MD

Arch Intern Med. 1993;153(8):973-980.

Abstract
Background
Given the same level of arterial pressure control, studies in diabetic animal models have demonstrated certain classes of antihypertensive medication to confer better overall preservation of renal histologic features and function as well as reduced albuminuria when compared with other agents. The present study was designed to assess whether any differences exist among antihypertensive agents with regard to progression of diabetic renal disease and albuminuria in human subjects.

Methods
The study was a randomized, prospective, parallel group design that evaluated the effects of a converting enzyme inhibitor (lisinopril; group 1), a calcium antagonist (diltiazem hydrochloride; group 2), and a combination of a loop diuretic and a β-blocker (furosemide and atenolol; group 3) in 30 subjects. All subjects received a low-salt, low-protein diet. Metabolic (blood glucose, cholesterol profiles, and urine urea nitrogen and sodium levels) as well as renal hemodynamic (renal blood flow and glomerular filtration rate) profiles and arterial pressure measurements were performed at various intervals during an 18-month period.

Results
Both groups 1 and 2 had significantly slower rates of decline in glomerular filtration rate compared with group 3. No significant differences were observed in renal hemodynamics between groups 1 and 2 at 18 months. Group 3 had the worst metabolic, lipid, and side-effect profile of any group. Reductions in albuminuria were not different between groups 1 and 2, but both were significantly reduced compared with group 3.

Conclusions
Given a similar level of arterial pressure control, both lisinopril and diltiazem slow progression of diabetic renal disease and reduce albuminuria to a greater extent than does the combination of a loop diuretic and β-adrenoreceptor antagonist. These drugs were also better tolerated and produced no adverse metabolic effects.

(Arch Intern Med. 1993;153:973-980)

Author Affiliations
From the Division of Nephrology, Department of Medicine, Ochsner Medical Institution, New Orleans, La (Drs Slataper and Bakris and Mss Vicknair and Sadler). Dr Bakris is now with the Departments of Preventive and Internal Medicine, Rush Presbyterian—St Luke's Medical Center, Chicago, Ill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Design and Statistical Aspects of the African American Study of Kidney Disease and Hypertension (AASK)
Gassman et al.
J. Am. Soc. Nephrol. 2003;14:S154-165.
ABSTRACT | FULL TEXT  

Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension
Swales and Williams
Journal of Renin-Angiotensin-Aldosterone System 2002;3:79-89.
ABSTRACT  

Effect of Angiotensin II Antagonist Eprosartan on Hyperglycemia-Induced Activation of Intrarenal Renin-Angiotensin System in Healthy Humans
Osei et al.
Hypertension 2000;36:122-126.
ABSTRACT | FULL TEXT  

Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview
Nielsen and Flyvbjerg
Nephrol Dial Transplant 2000;15:581-585.
FULL TEXT  

The Paradox of the Low-Renin State in Diabetic Nephropathy
PRICE et al.
J. Am. Soc. Nephrol. 1999;10:2382-2391.
ABSTRACT | FULL TEXT  

Antihypertensive Agents in Diabetic Patients: Great Benefits, Special Risks
Peters and Hsueh
Arch Intern Med 1999;159:541-542.
FULL TEXT  

Hyperglycemia and Angiotensin-Mediated Control of the Renal Circulation in Healthy Humans
Osei et al.
Hypertension 1999;33:559-564.
ABSTRACT | FULL TEXT  

Fixed Low-Dose Drug Combination for the Treatment of Hypertension
Chrysant
Arch Fam Med 1998;7:370-376.
ABSTRACT | FULL TEXT  

Effect of Calcium Channel or ß-Blockade on the Progression of Diabetic Nephropathy in African Americans
Bakris et al.
Hypertension 1997;29:744-750.
ABSTRACT | FULL TEXT  

1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension
National High Blood Pressure Education Program Wor
Arch Intern Med 1996;156:1938-1947.
ABSTRACT  

Long-term Effects of Antihypertensive Agents on Proteinuria and Renal Function
Maki et al.
Arch Intern Med 1995;155:1073-1080.
ABSTRACT  

ANTIHYPERTENSIVE THERAPY AND DIABETIC RENAL DISEASE
JWatch General 1993;1993:4-4.
FULL TEXT